Skip to Content

Join the 'Palonosetron' group to help and get support from people like you.

Palonosetron News

FDA Approves Akynzeo (netupitant and palonosetron) for Chemotherapy-Induced Nausea and Vomiting

Posted 14 Oct 2014 by Drugs.com

October 10, 2014 – The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron, approved in 2008, prevents nausea and vomiting during the acute phase (within the first 24 hours) after the start of cancer chemotherapy. Netupitant, a new drug, prevents nausea and vomiting during both the acute phase and delayed phase (from 25 to 120 hours) after the start of cancer chemotherapy. “Supportive care products, such as Akynzeo, help ease the nausea and vomiting patients may experience as a side effect of cancer chemotherapy,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Akynzeo’s effectiveness was established in two clinical trials ... Read more

Related support groups: Cancer, Nausea/Vomiting - Chemotherapy Induced, Palonosetron

Ask a Question

Further Information

Related Condition Support Groups

Nausea / Vomiting - Chemotherapy Induced, Nausea / Vomiting - Postoperative

Related Drug Support Groups

Aloxi

Palonosetron Patient Information at Drugs.com